menu
    • menu

    Company profile for Iksuda Therapeutics

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Iksuda Therapeutics is creating next-generation, class leading Antibody-Drug Conjugates (ADCs). Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies. We are building a pipeline of ADCs centred on: • PermaLink® – proprietary conjugation chemistry for improved ADC stability • Novel ultra-potent toxins for improved tumour killing • Novel antibodies targete...
    Iksuda Therapeutics is creating next-generation, class leading Antibody-Drug Conjugates (ADCs). Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies. We are building a pipeline of ADCs centred on: • PermaLink® – proprietary conjugation chemistry for improved ADC stability • Novel ultra-potent toxins for improved tumour killing • Novel antibodies targeted towards well-selected antigens associated primarily with solid tumours We are focused on providing more effective treatments for patients who have few options, with a particular focus on solid tumours

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Iksuda Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Newcastle Upon Tyne
    Telephone
    Telephone
    +44(0)191 6031680
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://iksuda.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/iksudatherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Iksuda To Unveil Oesophageal Cancer Data From IKS014 Phase 1
    Iksuda To Unveil Oesophageal Cancer Data From IKS014 Phase 1

    06 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260105552386/en/Iksuda-to-Present-Preliminary-Analysis-of-Oesophageal-Cancer-Data-From-Phase-1-study-of-IKS014-at-ASCO-Gastrointestinal-Cancer-Symposium

    BUSINESSWIRE
    06 Jan 2026
    Share Share
    Iksuda Presents Encouraging IKS014 Phase 1 Data At ESMO
    Iksuda Presents Encouraging IKS014 Phase 1 Data At ESMO

    21 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-21/iksuda-presents-encouraging-iks014-phase-1-data-at-esmo

    PHARMIWEB
    21 Oct 2025
    Share Share
    Iksuda To Present IKS014 Phase 1 Data At ESMO
    Iksuda To Present IKS014 Phase 1 Data At ESMO

    14 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-14/iksuda-to-present-iks014-phase-1-data-at-esmo

    PHARMIWEB
    14 Oct 2025
    Share Share
    Iksuda Therapeutics Receives FDA IND Clearance for IKS014
    Iksuda Therapeutics Receives FDA IND Clearance for IKS014

    30 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250630186021/en/Iksuda-Therapeutics-Receives-FDA-IND-Clearance-for-IKS014

    BUSINESSWIRE
    30 Jun 2025
    Share Share
    Iksuda Therapeutics doses first patient in IKS03 Trial
    Iksuda Therapeutics doses first patient in IKS03 Trial

    30 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250529137420/en/Iksuda-Therapeutics-announces-first-patient-successfully-dosed-in-phase-1-trial-evaluating-IKS03-in-advanced-B-cell-non-Hodgkin-lymphomas

    BUSINESSWIRE
    30 May 2025
    Share Share
    Iksuda to Present Growing ADC Pipeline at AACR
    Iksuda to Present Growing ADC Pipeline at AACR

    25 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250424028303/en/Iksuda-to-Present-Growing-ADC-Pipeline-at-AACR

    BUSINESSWIRE
    25 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search